Role of newer atypical antipsychotics in the management of treatment- resistant schizophrenia

CNS Drugs

Volumn 13, Issue 6, 2000, Pages 409-420

  Emsley, Robin A ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Department of Psychiatry ^*  (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; AMISULPRIDE; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; LOXAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

BINDING AFFINITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0034131178     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013060-00003     Document Type: Review

References (59)

1. 1. Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106-9
2. 2. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int J Psychopharmacol 1995; 10: 207-13
3. 3. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial ol olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55 (3): 250-8
4. 4. Meltzer H, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-90
5. 5. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95: 40-3
6. 6. Franz M, Lis S, Pluddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422-5
7. 7. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30
8. 8. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 53-60
9. 9. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14 (2): 87-96
10. 10. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receplor binding. Psychopharmacology (Berl.) 1996; 124 (1-2): 57-73
11. 11. Kumar V. Use of atypical agents in geriatric patients: a review. Int J Geriatr Psychopharmacology 1997; 1: 15-23
12. 12. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345 (8949): 557-62
13. 13. Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12 (2): 135-50
14. 14. Wirshing WC, Marder SR, Van Putten T, et al. Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, 1994
15. 15. Crow TJ, MacMillan JF, Johnson AL, et al. Northwick Park study of first episodes of schizophrenia II. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7
16. 16. Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8
17. 17. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993; 54 Suppl. 3: 13-7
18. 18. Marder SR. An approach to treatment resistance in schizophrenia. Br J Psychiatry 1999; Suppl. 37: 19-22
19. 19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
20. 20. Meltzer H. Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16 (4): 563-5
21. 21. Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 26-30
22. 22. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45 (9): 789-96
23. 23. Wahlbeck K, Cheine M, Essali A, et al. Clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990-9
24. 24. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151 (12): 1744-52
25. 25. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32 (4): 683-97
26. 26. Conley RR, Carpenter Jr WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154 (9): 1243-7
27. 27. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. J Psychopharmacol 1997; 11: 65-71
28. 28. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6): 825-35
29. 29. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155 (4): 499-504
30. 30. Green MF, Marshall Jr BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154 (6): 799-804
31. 31. Kern RS, Green MF, Marshall Jr BD, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 1998; 44 (8): 726-32
32. 32. Kern RS, Green MF, Marshall BD, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999; 25: 223-32
33. 33. Kee KS, Kern RS, Marshall BD, et al. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998; 31: 159-65
34. 34. Wirshing DA, Marshall Jr BD, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999; 156 (9): 1374-9
35. 35. Flynn SW, MacEwan GW, Altman S. et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 1998; 31 (1); 25-9
36. 36. Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996; 47 (12): 1382-4
37. 37. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155 (7): 914-20
38. 38. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999; 45 (4): 403-11
39. 39. Martin J, Gomez JC, Garcia BE, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997; 58 (11): 479-83
40. 40. Conley RR, Tamminga CA, Kelly DL, et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999; 46: 73-7
41. 41. Dursun SM, Gardner DM, Bird DC, et al. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 1999; 44: 701-4
42. 42. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998; 33: 95-101
43. 43. Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999; 19: 62-6
44. 44. Kumra A, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37: 377-85
45. 45. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine and haloperidol in schizophrenic patients with a history of, and a demonstrated, partial response to conventional antipsychotic treatment. Int J Psychopharmacol. In press
46. 46. Meltzer HY. Risperidone and clozapine for treatment-resistant schizophrenia [letter]. Am J Psychiatry 1999; 156 (7): 1126-7
47. 47. Rubin E. Risperidone and clozapine for treatment-resistant schizophrenia [letter]. Am J Psychiatry 1999; 156 (7): 1127
48. 48. Dunayevich E, Chatterjee A. Risperidone and clozapine for treatment-resistant schizophrenia [letter]. Am J Psychiatry 1999; 156 (7): 1127
49. 49. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]. Arch Gen Psychiatry 1989; 46 (7): 672
50. 50. May PS, Dencker J, Hubbard K, et al. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Wiesbaden: Vieweg, Branschweig, 1988: 22-3
51. 51. Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997; 58: 252-5
52. 52. Klieser E, Lehman E, Kinzler E, et al. Randomised, double blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15 Suppl. 1: 45S-51S
53. 53. Small JG, Miller MJ, Klapper MH. Risperidone versus clozapine in chronic schizophrenia [abstract no. NR724]. Poster presented at the annual meeting of the American Psychiatric Association: 1994 May; Philadelphia (PA)
54. 54. Daniel DG, Weinberger DR, Kleinman JE, et al. Risperidone versus clozapine in psychosis [abstract no. NR356]. Poster presented at the annual meeting of the American Psychiatric Association: 1994 May; Philadelphia (PA)
55. 55. Tollefson GD, Beasley-CM J, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154 (4): 457-65
56. 56. Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49 (5): 345-53
57. 57. Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33: 658-63
58. 58. Szigethy E, Brent S, Findling RL. Quetiapine for refractory schizophrenia. J Am Acad Child Adolesc Psychiatry 1998; 37: 1127-8
59. 59. Chincilla A, Vega M, Cebollada A, et al. A long term treatment with seroquel (quetiapine) in a severe schizophrenia patient. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S198-S199